openPR Logo
Press release

Asia-Pacific Colorectal Cancer Therapeutics Market Along With Leading Key Players - Taiho Pharma, Merck KGaA, Hutchison MediPharma, Sanofi, Eli Lilly and Bayer

02-18-2019 06:29 AM CET | Health & Medicine

Press release from: Colorectal Cancer Therapeutics Market

ResearchMoz

ResearchMoz

Researchmoz added Most up-to-date research on "Asia-Pacific Colorectal Cancer Therapeutics Market Along With Leading Key Players - Taiho Pharma, Merck KGaA, Hutchison MediPharma, Sanofi, Eli Lilly and Bayer" to its huge collection of research reports.

Colorectal cancer (CRC) is the most common cancer and the leading cause of cancer-related mortality globally. The five-year prevalence population for CRC in Asia-Pacific was 1.7 million in 2017. This figure has been gradually rising with the growing elderly population and increasingly Westernized lifestyles.

CRC is a leading cause of death worldwide, accounting for 0.77 million deaths in 2015. Over half of the incident cases of CRC are diagnosed in patients over the age of 50, and as the aged population is projected to grow, the prevalence of CRC is anticipated to increase, acting as a driver for revenue growth. The poor prognosis, particularly for patients with advanced disease, has created a pressing need for improved therapeutic options.

The CRC market is therefore shifting from a focus on generic chemotherapy regimens to a complex treatment landscape based on the presence of various molecular aberrations. The marketed products landscape comprises a wide range of treatment options, including EGFR-targeted therapies, angiogenesis inhibitors, multiple kinase inhibitors and new chemotherapies.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1880947

In the current market, RAS-wild-type and RAS-mutant patients can be treated with angiogenesis inhibitors such as Avastin, Cyramza and Zaltrap, while patients with RAS- or KRAS-wild-type mutations can be prescribed EGFR-targeted therapies such as Erbitux and Vectibix. However, significant unmet need remains for products that can treat BRAF-mutant CRC patients.
A therapy that targets mutant BRAF - encorafenib plus binimetinib - is being developed in the pipeline.

Scope
The CRC Asia-Pacific market will be valued at $7.9 billion in 2024, growing from $5.3 billion in 2017 at a CAGR of 6%.
How will immune checkpoint inhibitors such as Keytruda and Opdivo contribute to growth?
What effect will patent expirations of currently branded therapies have on market value?
The CRC pipeline is large and diverse, with a strong presence of mAbs and targeted therapies.
What are the common targets and mechanisms of action of pipeline therapies?
Will the pipeline address unmet needs such as the lack of targeted therapies available for BRAF-mutant CRC patients?
What implications will the increased focus on targeted therapies have on the future of CRC treatment?

Browse TOC @ https://www.researchmoz.us/colorectal-cancer-therapeutics-in-asiapacific-markets-to-2024-launch-of-premium-targeted-therapies-and-increasing-prevalence-to-drive-the-market-report.html/toc

Numerous late-stage pipeline therapies with a strong clinical record have the potential to enter the market over the forecast period.
How have the late-stage therapies performed in clinical trials?
How would the approval of encorafenib plus binimetinib to treat BRAF-mutant patients affect the competitive landscape, with no targeted therapy currently available to address this patient subset?
The market forecasts indicate that Japan will contribute the most to the Asia-Pacific market value due to the emergence of novel therapies.
How will the annual cost of therapy and market size vary between the five assessed Asia-Pacific markets?
How could changes in risk factors such as population age, obesity and lifestyle influence the market?
Licensing deals are the most common form of strategic alliance in CRC, with total deal values ranging from under $10m to over $1 billion.
How do deal frequency and value compare between target families and
molecule types?
What were the terms and conditions of key licensing deals?

Reasons to buy
Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
Visualize the composition of the CRC market in terms of the dominant therapies for each patient subset, along with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the market.
Analyze the CRC pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
Understand the potential of late-stage therapies with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
Predict CRC market growth in the five assessed Asia-Pacific markets, with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as the individual contributions of promising late-stage molecules to market growth.
Identify commercial opportunities in the CRC deals landscape by analyzing trends in licensing and co-development deals.

About ResearchMoz

ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

Mr. Nachiket
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Email: sales@researchmoz.us
Website @ http://www.researchmoz.us/
Tel: 866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-621-2074
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow us on Blogger @ http://summaryofmarketresearchreports.blogspot.in/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Asia-Pacific Colorectal Cancer Therapeutics Market Along With Leading Key Players - Taiho Pharma, Merck KGaA, Hutchison MediPharma, Sanofi, Eli Lilly and Bayer here

News-ID: 1594184 • Views:

More Releases from Colorectal Cancer Therapeutics Market

Rise In Demand : Asia-Pacific Colorectal Cancer Therapeutics Market Will Be Valued At $7.9 Billion In 2024, At A CAGR Of 6%
Rise In Demand : Asia-Pacific Colorectal Cancer Therapeutics Market Will Be Valu …
Albany, NY, 27th March : Recent research and the current scenario as well as future market potential of "Colorectal Cancer Therapeutics in Asia-Pacific Markets to 2024 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market" globally. Colorectal cancer (CRC) is the most common cancer and the leading cause of cancer-related mortality globally. The five-year prevalence population for CRC in Asia-Pacific was 1.7 million in 2017. This figure
Asia-Pacific Comprehensive Review of Colorectal Cancer Therapeutics Market and its Development
Asia-Pacific Comprehensive Review of Colorectal Cancer Therapeutics Market and i …
Researchmoz added Most up-to-date research on "Colorectal Cancer Therapeutics in Asia-Pacific Markets to 2023 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market" to its huge collection of research reports. Colorectal Cancer (CRC) is the most common cancer and the leading cause of cancer-related mortality globally. There were more than 1.4 million newly diagnosed CRC cases in 2012, accounting for 9.7% of the total number of cancer
Asia-Pacific Colorectal Cancer Therapeutics Market Booming with the Major Players Like Taiho Pharma, Merck KGaA, Eli Lilly, Roche, Sanofi and Bayer
Asia-Pacific Colorectal Cancer Therapeutics Market Booming with the Major Player …
Researchmoz added Most up-to-date research on "Asia-Pacific Colorectal Cancer Therapeutics Market Booming with the Major Players Like Taiho Pharma, Merck KGaA, Eli Lilly, Roche, Sanofi and Bayer" to its huge collection of research reports. Colorectal cancer (CRC) is the most common cancer and the leading cause of cancer-related mortality globally. The five-year prevalence population for CRC in Asia-Pacific was 1.7 million in 2017. This figure has been gradually rising with the
Major Players In Colorectal Cancer Therapeutics in Asia-Pacific Market to 2023 - Merck KGaA, Eli Lilly, Sanofi, Bayer/Onyx and Taiho Pharma
Major Players In Colorectal Cancer Therapeutics in Asia-Pacific Market to 2023 - …
Researchmoz added Most up-to-date research on "Major Players In Colorectal Cancer Therapeutics in Asia-Pacific Market to 2023 - Merck KGaA, Eli Lilly, Sanofi, Bayer/Onyx and Taiho Pharma" to its huge collection of research reports. Colorectal Cancer (CRC) is the most common cancer and the leading cause of cancer-related mortality globally. There were more than 1.4 million newly diagnosed CRC cases in 2012, accounting for 9.7% of the total number of cancer

All 5 Releases


More Releases for CRC

Behavioral Rehabilitation Market – Future Trends Landscape 2025 | CRC Health, …
Behavioral Rehabilitation Market: Snapshot People might get several behavioral addictions due to various reasons, and these addictions can severely harm their health from a long term perspective. Most of the addictions might not go away by themselves. To resolve such issues, highly reliable methodologies are needed, and behavioral rehabilitation is a set of techniques that could achieve the same if utilized properly. Behavioral addiction treatments and rehabilitation activities have been going since
Behavioral Rehabilitation Market - Global Trends 2025 | CRC Health, Magellan Hea …
Behavioral Rehabilitation Market: Snapshot People might get several behavioral addictions due to various reasons, and these addictions can severely harm their health from a long term perspective. Most of the addictions might not go away by themselves. To resolve such issues, highly reliable methodologies are needed, and behavioral rehabilitation is a set of techniques that could achieve the same if utilized properly. Request Sample Copy of the Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=2579 Behavioral addiction treatments
Global Caulks & Sealants Market Forecast 2018-2025 DuPont , 3M , C.R. Laurence …
Global Caulks & Sealants Market This report researches the worldwide Caulks & Sealants market size (value, capacity, production and consumption) in key regions like North America, Europe, Asia Pacific (China, Japan) and other regions.  This study categorizes the global Caulks & Sealants breakdown data by manufacturers, region, type and application, also analyzes the market status, market share, growth rate, future trends, market drivers, opportunities and challenges, risks and entry barriers, sales channels,
Behavioral Rehabilitation Market -Overview On Ongoing Trends 2025 | CRC Health, …
Behavioral Rehabilitation Market: Snapshot People might get several behavioral addictions due to various reasons, and these addictions can severely harm their health from a long term perspective. Most of the addictions might not go away by themselves. To resolve such issues, highly reliable methodologies are needed, and behavioral rehabilitation is a set of techniques that could achieve the same if utilized properly. Request Sample Copy of the Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=2579 Behavioral addiction treatments
Innovative Manufacturing CRC and Germany’s Fraunhofer-Gesellschaft partner to …
Framework agreement to catalyse uptake of Industry 4.0 within Australia’s manufacturing industry A framework engagement agreement (The Agreement), signed today by the Innovative Manufacturing CRC (IMCRC) and Germany’s Fraunhofer-Gesellschaft, is set to significantly increase awareness and uptake of Industry 4.0 within the Australian manufacturing industry. The Agreement establishes a broad framework governing IMCRC and Fraunhofer projects focusing on the exchange of knowledge and the proliferation of Industry 4.0 technologies and research. Future projects
Global Semiconductor Double Detection Experiments Market 2017 - Crc Press, Axcel …
The Semiconductor Double Detection Experiments Market 2017 examines the performance of the Semiconductor Double Detection Experiments market, enclosing an in-depth judgment of the Semiconductor Double Detection Experiments market state and the competitive landscape globally. This report analyzes the potential of Semiconductor Double Detection Experiments market in the present as well as the future prospects from various angles in detail. The Global Semiconductor Double Detection Experiments Market 2017 report includes Semiconductor Double